Fibrinolysis and SARS-CoV-2

Authors

Keywords:

fibrinolysis, thrombosis, SARS-CoV-2, COVID-19, PAI-1.

Abstract

The regulation of the fibrinolysis system is mediated by specific molecular interactions between its main components and by the synthesis and subsequent release from endothelial cells of plasminogen activators and inhibitors. Therefore, an increase in the activity of the fibrinolysis system favors the appearance of bleeding disorders, while a defect in fibrinolytic activity may predispose to thrombosis. Alterations in fibrinolysis have also been reported in patients with SARS-CoV-2. Attenuation of the plasminogen activation system leads to abnormal fibrin turnover in the alveolar space with the development of thrombosis. Plasma PAI-1 levels have been reported to be a risk factor for poor prognosis and mortality in patients with Covid-19.

Published

2023-04-25

How to Cite

1.
Urrutia Febles Y, Castillo González DC. Fibrinolysis and SARS-CoV-2. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2023 Apr. 25 [cited 2025 Feb. 7];39(1). Available from: https://revhematologia.sld.cu/index.php/hih/article/view/1729

Issue

Section

HEMOSTASIA Y TROMBOSIS